Syros to Present at 37th Annual J.P. Morgan Healthcare Conference

Jan 03, 2019 08:01 am

CAMBRIDGE, Mass. --

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2019 objectives, at the 37th Annual J.P. Morgan Healthcare Conference. Details are as follows:

37^th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 10
Time: 9:00 a.m. PST (12:00 p.m. EST)
Location: Westin St. Francis Hotel, 335 Powell St., San Francisco, CA

The presentation will be followed by a question and answer session.

Live webcasts of the presentation and question and answer session will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of both webcasts will be available for approximately 30 days.

About Syros Pharmaceuticals

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005005/en/

Media Contact:
Naomi Aoki
Syros Pharmaceuticals
617-283-4298
[email protected]

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Return to Top

Disclaimer :: Use of this site is subject to, and your continued use constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information. INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion; however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR® or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment. Users should always consult with and obtain advice from their professional licensed financial advisor, including their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment or trading securities do so with caution. Users should perform full due diligence and investigate any security fully before making an investment or before the execution of a security trade based upon information learned through INK. Investors should obtain annual reports and other company information to complete their own due diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this website. On this site, there may be third party content, content from authors or links to third-party sites or pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI® is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.

Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.

You are here

Syros to Present at 37th Annual J.P. Morgan Healthcare Conference